Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ESG206 in primary Sjögren's syndrome
NCT07375524Phase 2Not yet recruiting
- Sponsor
- Shanghai Escugen Biotechnology Co., Ltd.
- Start
- Mar 2026
- Primary completion
- Dec 2027
- Modality
- Prophylactic Vaccines, Therapeutic Vaccines, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of ESG206, sponsored by Shanghai Escugen Biotechnology Co., Ltd.. Planned start Mar 2026; status: not yet recruiting.
02
Drugs
ESG206
Beyond the preview
Go deeper on NCT07375524.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07375524.